确定乙酰化酶表型的简化方法。
Simplified method for determining acetylator phenotype.
作者信息
Schröder H
出版信息
Br Med J. 1972 Aug 26;3(5825):506-7. doi: 10.1136/bmj.3.5825.506.
Abstract
A chemical method has been developed for estimating the acetylator phenotype without the use of special equipment. One urine specimen taken after ingestion of sulphadimidine, sulphapyridine, or sulphasalazine is required. The acetylator phenotype was assessed correctly in 150 urine specimens from 100 healthy subjects. Between 15 and 25 specimens can be determined hourly. Urine specimens for the test can be stored for two weeks at 37 degrees C without any loss of drugs or their metabolites.
摘要
已开发出一种无需使用特殊设备就能估算乙酰化表型的化学方法。需要一份在摄入磺胺二甲嘧啶、磺胺吡啶或柳氮磺胺吡啶后采集的尿液样本。对100名健康受试者的150份尿液样本正确评估了乙酰化表型。每小时可测定15至25份样本。用于该检测的尿液样本可在37摄氏度下保存两周，而不会出现任何药物或其代谢物的损失。
相似文献
1
Simplified method for determining acetylator phenotype.确定乙酰化酶表型的简化方法。
Br Med J. 1972 Aug 26;3(5825):506-7. doi: 10.1136/bmj.3.5825.506.
2
Acetylator phenotype and adverse effects of sulphasalazine in healthy subjects.健康受试者中乙酰化代谢表型与柳氮磺胺吡啶的不良反应
Gut. 1972 Apr;13(4):278-84. doi: 10.1136/gut.13.4.278.
3
Determination of the acetylator phenotype and pharmacokinetics of some sulphonamides in man.人体中某些磺胺类药物乙酰化表型及药代动力学的测定
Clin Pharmacokinet. 1980 May-Jun;5(3):274-94. doi: 10.2165/00003088-198005030-00006.
4
Possible optimization of sulphadimidine dosage for acetylator phenotyping.磺胺二甲嘧啶剂量用于乙酰化酶表型分析的可能优化
Jpn J Pharmacol. 1991 Aug;56(4):531-4. doi: 10.1254/jjp.56.531.
5
Simple method for determining isoniazid acetylator phenotype.测定异烟肼乙酰化酶表型的简单方法。
Br Med J. 1970 Aug 8;3(5718):324-5. doi: 10.1136/bmj.3.5718.324.
6
Clinical pharmacokinetics of sulphasalazine.柳氮磺胺吡啶的临床药代动力学
Clin Pharmacokinet. 1976 Nov-Dec;1(6):406-25. doi: 10.2165/00003088-197601060-00002.
7
Comparison between serum and urinary sulphadimidine acetylation as predictors of isoniazid acetylator status in patients with pulmonary tuberculosis.肺结核患者血清与尿液中磺胺二甲嘧啶乙酰化作为异烟肼乙酰化状态预测指标的比较
Indian J Chest Dis Allied Sci. 1996 Jan-Mar;38(1):5-11.
8
Ageing and acetylator phenotype as determined by administration of sulphadimidine.通过给予磺胺二甲嘧啶确定的衰老与乙酰化酶表型。
Eur J Clin Pharmacol. 1985;28(4):485-6. doi: 10.1007/BF00544374.
9
10
Colorimetric or HPLC method for acetylator phenotyping with sulfadimidine?用磺胺二甲嘧啶进行乙酰化酶表型分型的比色法或高效液相色谱法？
Acta Pharmacol Toxicol (Copenh). 1982 Jan;50(1):75-7. doi: 10.1111/j.1600-0773.1982.tb00942.x.
引用本文的文献
1
Acetylator phenotype and the clinical pharmacology of slow-release procainamide.乙酰化表型与普鲁卡因胺控释剂的临床药理学。
Br J Clin Pharmacol. 1976 Dec;3(6):1023-6. doi: 10.1111/j.1365-2125.1976.tb00352.x.
2
Polymorphic acetylation: lack of influence of rheumatic disease activity and concomitant drug administration.多态性乙酰化：风湿性疾病活动及同时给药的无影响
Rheumatol Int. 1995;14(6):257-60. doi: 10.1007/BF00262093.
3
Determination of the acetylator phenotype and pharmacokinetics of some sulphonamides in man.人体中某些磺胺类药物乙酰化表型及药代动力学的测定
Clin Pharmacokinet. 1980 May-Jun;5(3):274-94. doi: 10.2165/00003088-198005030-00006.
4
Antipyrine elimination by patients under treatment with monoamine oxidase inhibitors.接受单胺氧化酶抑制剂治疗的患者的安替比林消除情况。
Br J Clin Pharmacol. 1980 Jan;9(1):21-5. doi: 10.1111/j.1365-2125.1980.tb04791.x.
5
Acetylator status and diabetic neuropathy.乙酰化状态与糖尿病神经病变
Diabetologia. 1982 Jun;22(6):441-4. doi: 10.1007/BF00282587.
6
Comparative pharmacokinetics of co-trifamole and co-trimoxazole to 'steady state' in normal subjects.复方三嗪酰胺与复方新诺明在正常受试者中达“稳态”的比较药代动力学
Br J Clin Pharmacol. 1982 Sep;14(3):437-43. doi: 10.1111/j.1365-2125.1982.tb02004.x.
7
Hydrallazine in hypertension: is there a safe dose?肼屈嗪治疗高血压：是否存在安全剂量？
Br Med J. 1980 Aug 2;281(6236):353-4. doi: 10.1136/bmj.281.6236.353.
8
Endralazine, a new peripheral vasodilator. Evaluation of safety and efficacy over a 3 year period.恩屈嗪，一种新型外周血管扩张剂。三年期间安全性和有效性评估。
Eur J Clin Pharmacol. 1983;24(3):301-5. doi: 10.1007/BF00610045.
9
A simple test for acetylator phenotype using caffeine.一种使用咖啡因检测乙酰化酶表型的简单测试。
Br J Clin Pharmacol. 1984 Apr;17(4):459-64. doi: 10.1111/j.1365-2125.1984.tb02372.x.
10
Survey of the human acetylator polymorphism in spontaneous disorders.自发性疾病中人类乙酰化多态性的调查。
J Med Genet. 1984 Aug;21(4):243-53. doi: 10.1136/jmg.21.4.243.
本文引用的文献
1
HUMAN ACETYLATION POLYMORPHISM.人类乙酰化多态性
J Lab Clin Med. 1964 Mar;63:394-403.
2
The polymorphic acetylation of dapsone in man.氨苯砜在人体内的多态性乙酰化作用。
Clin Pharmacol Ther. 1971 Mar-Apr;12(2):225-38. doi: 10.1002/cpt1971122part1225.
3
Sulphadimidine acetylation test for classification of patients as slow or rapid inactivators of isoniazid.用于将患者分类为异烟肼慢灭活者或快灭活者的磺胺二甲嘧啶乙酰化试验。
Br Med J. 1970 Aug 29;3(5721):495-7. doi: 10.1136/bmj.3.5721.495.
4
Simple method for determining isoniazid acetylator phenotype.测定异烟肼乙酰化酶表型的简单方法。
Br Med J. 1970 Aug 8;3(5718):324-5. doi: 10.1136/bmj.3.5718.324.
5
Diphenylhydantoin intoxication. A complication of isoniazid therapy.二苯妥英中毒。异烟肼治疗的一种并发症。
Am Rev Respir Dis. 1970 Mar;101(3):377-84. doi: 10.1164/arrd.1970.101.3.377.
6
An improved and simplified method of detecting the acetylator phenotype.一种检测乙酰化酶表型的改良简化方法。
J Med Genet. 1969 Dec;6(4):405-7. doi: 10.1136/jmg.6.4.405.
7
Isoniazid and ethionamide serum levels and inactivation in Finnish subjects.芬兰受试者中异烟肼和乙硫异烟胺的血清水平及灭活情况。
Scand J Respir Dis. 1969;50(2):110-24.
8
The polymorphic acetylation of sulphapyridine in man.人磺胺吡啶的多态性乙酰化作用。
J Med Genet. 1972 Jun;9(2):168-71. doi: 10.1136/jmg.9.2.168.
9
The use of the autoanalyzer to determine the acetylator phenotype.使用自动分析仪来确定乙酰化酶表型。
J Med Genet. 1972 Mar;9(1):57-9. doi: 10.1136/jmg.9.1.57.
Zotero 插件